New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2014
05:43 EDTPSTIPluristem Therapeutics submits FDA orphan drug application for PLX-PAD
Pluristem Therapeutics announced it is submitting its application to the FDA requesting the company to be granted Orphan Drug Designation for its PLacental eXpanded, or PLX-PAD, cells in the treatment of severe preeclampsia. Pluristem has successfully received Orphan Drug Designation from the FDA for its PLX cells in two other indications: the treatment of aplastic anemia; and the treatment of Buerger's disease.
News For PSTI From The Last 14 Days
Check below for free stories on PSTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PSTI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use